FindMyKOL

Mujibur Majumder, MD

Basic profile

Brookdale University Hospital and Medical Center

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBrooklyn, NY · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLEmergingFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mujibur Majumder is a Respiratory physician affiliated with Brookdale University Hospital and Medical Center. OpenAlex indexes 18 publications with 216 citations (h-index 5).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
18publications

Publications indexed by OpenAlex. Counts exclude supporting files.

216citations

Citations across these publications.

5h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
49companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

49 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • GSK
    Program year20253 paymentsResearch
    $15,092
  • AstraZeneca
    Program year20252 paymentsResearch
    $5,961
  • Actelion Pharmaceuticals US, Inc.
    Program year20258 payments
    $340
All 123 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    29.4%
    Statin8.2%
    Atorvastatin Calcium43%Simvastatin31%Rosuvastatin Calcium22%Lovastatin3%
    Part D<11 patients
    ACE inhibitor4.5%
    Lisinopril47%Enalapril Maleate29%Lisinopril-Hydrochlorothiazide15%Ramipril10%
    Part D<11 patients

    + 12 more classes in this area

  • Metabolism & gastrointestinal

    25.8%
    Provitamin D2 Compound5.2%
    Vitamin D2100%
    Part D≥54 patients
    Proton pump inhibitor4.9%
    Omeprazole75%Pantoprazole Sodium16%Esomeprazole Magnesium5%Omeprazole-Sodium Bicarbonate4%
    Part D<11 patients

    + 14 more classes in this area

  • Respiratory

    19.1%
    Corticosteroid7.1%
    Trelegy Ellipta34%Breo Ellipta29%Symbicort17%Fluticasone Propionate16%Mometasone Furoate5%
    Part D<11 patients
    beta2-Adrenergic Agonist6.5%
    Albuterol Sulfate Hfa90%Ventolin Hfa10%
    Part D≥106 patients

    + 5 more classes in this area

Where care is delivered (Part B)50.8% facility · 49.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”